7A
Valuation Multiples Analysis
CME Group Inc. (CME) currently presents a mixed valuation picture, exhibiting some metrics slightly below its historical 5-year averages while maintaining an 'In-Line' position relative to its industry peers. The company's P/E multiple of 24.3x is modestly below its 5-year average of 25.9x, suggesting a slight de-rating compared to its recent history. Similarly, its EV/EBITDA of 17.0x is also below its 5-year average of 17.8x, and notably trades at an 18.8% discount to the peer median of 20.9x.
Conversely, CME's Price-to-Book (P/B) ratio of 3.42x is significantly above its 5-year average of 2.54x, indicating that the market is assigning a higher value to its equity relative to its book assets than it has historically. Despite this increase, its P/B is essentially in line with the peer median of 3.43x. The overall valuation trend for CME is described as 'Stable,' implying that its multiples have not experienced significant expansion or contraction recently, maintaining its 'Above Average' historical valuation position within the market.
These multiples suggest that while the market continues to assign a premium to CME, especially on a P/B basis, there may be some moderation in expectations compared to its peak historical P/E and EV/EBITDA levels. The discount on EV/EBITDA relative to peers could signal an attractive entry point for investors seeking exposure to the financial exchanges sector, assuming underlying fundamentals remain robust and justify its premium P/B.
Key Findings
- CME's P/E and EV/EBITDA multiples are currently trading slightly below their respective 5-year historical averages, suggesting a modest de-rating from recent historical highs.
- The company's Price-to-Book (P/B) ratio has significantly expanded relative to its 5-year average, indicating increased market confidence in its asset base or return on equity over time.
- CME trades at an attractive 18.8% discount on an EV/EBITDA basis compared to its peer median, potentially signaling a relative undervaluation opportunity for enterprise value-focused investors.
- Despite some metrics being below historical averages, CME's overall 'Above Average' historical valuation position and 'Stable' trend suggest the market continues to assign a premium to its business model and market position.
Company Valuation Highlights
CME:
CME Group Inc. exhibits a nuanced valuation profile. Its P/E of 24.3x is 6.1% below its 5-year average of 25.9x and slightly below the peer median of 24.8x, suggesting a modest historical de-rating but an 'In-Line' peer valuation. The EV/EBITDA multiple of 17.0x is also below its 5-year average of 17.8x and notably trades at an 18.8% discount to the peer median of 20.9x, presenting a potentially attractive valuation on an enterprise basis. Conversely, CME's P/B of 3.42x is significantly above its 5-year average of 2.54x, signaling a re-rating of its book assets, though it remains in line with the peer median of 3.43x. With a stable valuation trend and a historical position of 'Above Average', these multiples indicate that while CME continues to command a premium valuation, particularly on a P/B basis, the market may be pricing in slightly more conservative growth expectations compared to its recent past, especially on an EV/EBITDA basis relative to its peers. The P/S ratio stands at 15.06x. Investors should consider the EV/EBITDA discount to peers as a potential opportunity, while acknowledging the elevated P/B relative to its own history.
| Company | P/E | Hist Avg | Fwd P/E | PEG | P/B | EV/EBITDA | P/S | Position |
|---|---|---|---|---|---|---|---|---|
| CME | 24.3x | 25.9x | 25.3x | 3.86x | 3.42x | 17.0x | 15.06x | Above Average |
Historical Percentile Position
Where current multiples sit relative to full historical range (higher percentile = more expensive vs history)
| Company | P/E %ile | P/E Range | P/B %ile | P/B Range | EV/EBITDA %ile | P/S %ile |
|---|---|---|---|---|---|---|
| CME | 36th | 12.2x - 33.9x | 91th | 1.48x - 3.42x | 45th | 82th |
Peer Valuation Comparison
How each company's valuation compares to its industry peers
CME vs 10 Peers
In-LineP/E Ratio
24.3x
Peer Median: 24.8x
(-2.2%)
P/B Ratio
3.42x
Peer Median: 3.43x
(-0.3%)
EV/EBITDA
17.0x
Peer Median: 20.9x
(-18.8%)
P/S Ratio
15.06x
Peer Median: 4.73x
(+218.1%)
View all 10 peers
| Peer | P/E | P/B | EV/EBITDA | P/S | Market Cap |
|---|---|---|---|---|---|
| CME | 24.3x | 3.42x | 17.0x | 15.06x | - |
| ICE | 28.7x | 3.28x | 17.2x | 7.50x | $94.8B |
| COIN | 42.0x | 3.58x | 28.0x | 8.27x | $53.2B |
| MCO | 34.1x | 20.71x | 22.8x | 10.84x | $83.7B |
| BMO | 15.1x | 1.60x | 34.1x | 1.77x | $136.4B |
| MMC | 21.4x | 5.90x | 14.7x | 3.32x | $89.7B |
| BAM | 29.9x | 8.35x | 24.5x | 15.40x | $74.3B |
| MFG | 15.5x | 1.45x | 14.5x | 1.98x | $16.18T |
| NDAQ | 28.2x | 4.13x | 19.1x | 6.14x | $50.5B |
| IBN | 17.7x | 2.69x | 9.6x | 3.06x | $9.40T |
| BNS | 14.5x | 1.48x | 28.7x | 1.96x | $121.2B |
| Peer Median | 24.8x | 3.43x | 20.9x | 4.73x | - |
7B
Enterprise Value Analysis
CME Group Inc. (CME) exhibits a robust financial profile with a total Enterprise Value (EV) of $97.21 billion. This valuation is notably driven by its substantial market capitalization of $115.04 billion, rather than debt. In fact, CME maintains a net cash position, with $4.42 billion in cash against total debt of $3.42 billion, resulting in a negative net debt of -$1.00 billion. This indicates that the company holds more cash than its total outstanding debt, a strong indicator of financial health and flexibility.
From a valuation multiple perspective, CME trades at an EV/EBITDA of 17.0x and an EV/Sales of 14.91x. These multiples suggest that the market assigns a premium valuation to CME's earnings and revenue streams. Such elevated multiples are often indicative of companies with strong market positions, consistent profitability, and attractive growth prospects within their respective industries. Investors are effectively paying a higher price per unit of earnings or sales, reflecting confidence in the company's future performance and asset quality.
Key Findings
- CME Group's Enterprise Value of $97.21 billion is predominantly driven by its equity value, with a significant net cash position rather than reliance on debt.
- The company's EV/EBITDA of 17.0x and EV/Sales of 14.91x indicate a premium market valuation, suggesting investor confidence in its strong market position and profitability.
- CME maintains a robust balance sheet with negative net debt of -$1.00 billion, providing substantial financial flexibility and reducing financial risk.
Leverage Assessment
CME Group Inc. demonstrates an exceptionally strong capital structure, characterized by very low leverage. Its Net Debt/EBITDA ratio stands at -0.18x, confirming its net cash position relative to its operating earnings. This places CME firmly in the 'Low' leverage tier, as indicated by the portfolio's leverage distribution. A negative net debt position offers significant financial flexibility, enabling the company to pursue strategic investments, engage in share buybacks, or increase dividends without incurring additional debt. It also provides a substantial buffer against potential economic downturns or unexpected operational challenges, significantly reducing the company's financial risk profile. For investors, this signals a high-quality balance sheet that can support long-term value creation and resilience.
| Company | Market Cap | EV | Net Debt | EV/EBITDA | Hist Avg | EV/Sales | EV/FCF | Leverage |
|---|---|---|---|---|---|---|---|---|
| CME | $115.04B | $97.21B | $-1.00B | 17.0x | 17.8x | 14.91x | N/A | Low |
Leverage Analysis
| Company | Net Debt/EBITDA | Hist Avg | Hist Range | Debt % of EV | Leverage Tier |
|---|---|---|---|---|---|
| CME | -0.18x | 4.38x | -0.18x - 15.67x | 3.5% | Low |
7C
DCF & Intrinsic Value Analysis
Our Discounted Cash Flow (DCF) analysis provides an intrinsic valuation perspective for CME Group Inc. (CME), factoring in both historical performance trends and forward-looking analyst expectations. The current macroeconomic environment, characterized by a 10-year Treasury yield of 4.15% and a BAA credit spread of 1.75%, influences the cost of capital. While higher interest rates compared to the ultra-low period of 2020-2021 generally lead to higher discount rates and thus lower valuations, CME's notably low Beta of 0.26 helps to keep its Weighted Average Cost of Capital (WACC) at a relatively contained 4.99%. The tight BAA spread further indicates a 'risk-on' sentiment in the market, resulting in a lower dynamic market risk premium (3.25%) and contributing to a more favorable WACC calculation.
For CME Group, both our Historical DCF and Analyst DCF models consistently point towards a significant undervaluation relative to its current market price of $320.00. The Historical DCF, which projects future cash flows based on CME's robust 10-year FCF CAGR of 11.6%, suggests an intrinsic value of $725.40, representing a substantial 126.7% upside. The Analyst DCF, which incorporates forward-looking revenue estimates from Wall Street analysts, yields a more conservative yet still highly attractive intrinsic value of $511.34, indicating an upside of 59.8%. The divergence between these two models suggests that while CME has demonstrated strong historical free cash flow growth, analysts may be projecting a somewhat moderated growth trajectory going forward, perhaps anticipating a more normalized market environment or competitive landscape compared to past periods of high volatility that benefited financial exchanges. Despite this, the consensus from both models is clear: CME appears to be trading well below its intrinsic value.
Key Findings
- CME Group Inc. (CME) is indicated as significantly undervalued by both Historical and Analyst DCF models, with potential upsides of 126.7% and 59.8% respectively.
- The Historical DCF ($725.40) is substantially higher than the Analyst DCF ($511.34), suggesting that analysts' forward-looking growth expectations for CME are more conservative than its impressive 10-year historical Free Cash Flow (FCF) CAGR of 11.6%.
- CME's low Beta (0.26) contributes to a relatively low WACC of 4.99%, helping to support higher intrinsic valuations despite the current higher interest rate environment.
- The market's current valuation of CME at $320.00 appears to significantly discount its strong cash flow generation capabilities and consistent historical growth, potentially due to concerns about future growth normalization, cyclicality in trading volumes, or market perception of mature companies.
DCF Verdicts by Company
CME:
Significantly Undervalued
Risk-Free Rate (10Y Treasury):
4.15%
Market Risk Premium:
3.25%
BAA Spread:
1.75%
Terminal Growth Rate:
Varies by sector (2.0% - 3.5%)
Methodology Note:
- Market Risk Premium: Calculated dynamically based on credit spreads.
Formula:
ERP = 3.0% + (BAA Spread - 1.5%). When spreads are tight, ERP is lower; when spreads widen, ERP increases. - Terminal Growth Rate: Sector-based assumptions: Technology, Communication Services: 3.5% | Healthcare, Consumer Cyclical: 3.0% | Industrials, Financials, Consumer Defensive, Materials: 2.5% | Energy, Utilities, Real Estate: 2.0%
- Shares Outstanding: Adjusted for historical buyback trends when applicable.
| Company | Current Price | Historical DCF | Upside | Analyst DCF | Upside | Verdict |
|---|---|---|---|---|---|---|
| CME | $320.00 | $725.40 | +126.7% | $511.34 | +59.8% | Significantly Undervalued |
CME – CME Group Inc.
WACC Calculation
| Risk-Free Rate (Rf) | 4.15% |
| Beta (β) | 0.26 |
| Market Risk Premium | 5.50% |
| Cost of Equity (Ke = Rf + β × MRP) | 5.00% |
| Cost of Debt (after-tax) | 4.66% |
| WACC | 4.99% |
Historical Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| FCF ($B) | $2.3B | $3.0B | $3.4B | $3.6B | $4.2B |
| FCF Margin (%) | 48.5% | 59.1% | 60.5% | 58.7% | 64.3% |
FCF CAGRs: 5Y: 10.7% | 10Y: 11.6% | Avg FCF Margin (5Y): 58.2%
DCF Valuation (Two Methods)
| Component | Historical Method (10Y CAGR projection) |
Analyst Method (Revenue × FCF Margin) |
|---|---|---|
| Growth Assumption | 11.6% (10Y CAGR) | Analyst Revenue Est. × 58.2% margin |
| PV of Projected FCF | $25.27B | $20.37B |
| Terminal Value | $299.21B | $207.27B |
| PV of Terminal Value | $234.61B | $162.52B |
| Enterprise Value | $259.88B | $182.89B |
| (-) Net Debt | $-1.00B | $-1.00B |
| Equity Value | $260.88B | $183.89B |
| Intrinsic Value per Share | $725.40 | $511.34 |
| vs Current Price ($320.00) | +126.7% | +59.8% |
Sensitivity Analysis (Historical Method)
Intrinsic value per share varying WACC and Terminal Growth Rate
| WACC ↓ / TG → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 3.0% | $1255 | $1852 | $3645 | N/A | N/A |
| 4.0% | $748 | $921 | $1208 | $1783 | $3508 |
| 5.0% | $531 | $610 | $721 | $887 | $1164 |
| 6.0% | $411 | $455 | $512 | $589 | $695 |
| 7.0% | $334 | $362 | $397 | $439 | $494 |
Current price: $320.00 | Highlighted row shows base case WACC (4.99%)
Verdict:
Significantly Undervalued
(Combined upside: +93.2%, DCF Confidence: Medium)
DCF Summary Comparison
| Company | Current Price | Historical DCF | Analyst DCF | Combined Upside | Verdict |
|---|---|---|---|---|---|
| CME | $320.00 | $725.40 (+126.7%) | $511.34 (+59.8%) | +93.2% | Significantly Undervalued |
7D
Analyst vs Market Valuation
CME Group Inc. (CME) is currently trading at $320.00, slightly above the analyst consensus price target of $311.83. This implies a modest potential downside of 2.6% from the current share price, aligning with a prevalent 'Hold' sentiment among covering analysts. The consensus target has shown a modest upward trajectory over the past year, moving from $304.38 a year ago to the current $311.83, suggesting a stable, albeit not dramatically bullish, outlook from the analyst community.
Analysts anticipate continued earnings growth for CME, as evidenced by a significant contraction in the company's P/E multiple from a trailing twelve-month (TTM) 28.5x to a forward P/E of 25.3x. This 11.1% reduction in the P/E multiple for future earnings indicates expectations for robust earnings per share expansion in the near term. The stock is covered by 9 analysts, providing a reasonable level of institutional scrutiny, though the implied downside to the consensus target suggests that the current valuation already reflects much of the anticipated growth.
Key Findings
- CME Group is currently trading at $320.00, which is 2.6% above the analyst consensus target of $311.83, suggesting limited immediate upside potential according to Wall Street.
- Analyst price targets have shown a stable to modestly increasing trend over the past year, with the consensus target moving from $304.38 a year ago to $311.83 currently.
- The P/E multiple is expected to contract from a TTM 28.5x to a Forward 25.3x, indicating analyst expectations for strong near-term earnings growth.
- The analyst target range for CME is moderately wide, spanning from $300.00 (-6.2%) to $340.00 (+6.2%), implying some divergence in views regarding the company's fair value and future prospects, despite the consensus 'Hold' rating.
Price Target Trend Analysis
The modest increase in CME's consensus price target from $304.38 a year ago to $311.83 today, coupled with a 'Stable' trend, signals that analyst sentiment has remained consistent and mildly positive over the longer term. However, the current price trading above the consensus target suggests that the market has already priced in much of this sentiment, indicating that analysts see the stock as fairly valued or slightly overvalued at its current level, rather than presenting a compelling buy opportunity based on price targets alone.
P/E Trajectory Analysis
The notable contraction in CME's P/E multiple from 28.5x (TTM) to 25.3x (Forward) implies that analysts are forecasting significant earnings growth for the company in the upcoming periods. This 'P/E compression' is a positive indicator, suggesting that the market expects CME to deliver strong financial performance that will make its future earnings cheaper relative to its current share price. For investors, this trajectory suggests that future earnings are projected to expand at a rate faster than the current stock price appreciation, which could support the current valuation or provide future upside if growth exceeds expectations.
Analyst Price Targets
| Company | Current Price | Target Consensus | Target Low | Target High | Upside | Analysts | Sentiment |
|---|---|---|---|---|---|---|---|
| CME | $320.00 | $311.83 | $300.00 | $340.00 | -2.6% | 9 | Hold |
Forward Estimates & P/E Comparison
Comparing trailing (TTM) vs forward P/E reveals market expectations for earnings growth
| Company | Forward EPS | Forward Revenue | TTM P/E | Forward P/E | P/E Change | Estimate Year |
|---|---|---|---|---|---|---|
| CME | $12.64 | $7.31B | 28.5x | 25.3x | -11.1% (Strong growth expected) | FY2027 |
Reading P/E Change: Negative change (TTM P/E > Forward P/E) suggests analysts expect earnings growth.
Positive change indicates earnings may decline. Large differences warrant investigation into the growth story.
7E
Valuation Summary & Investment Implications
CME Group Inc. (CME) currently trades at $320.00, aligning closely with our median implied value of $317.45, suggesting the company is fairly valued based on a composite of six distinct valuation methodologies. A majority of the peer-based valuation methods and the Wall Street analyst consensus converge tightly around the current market price. Specifically, the P/E (Peer) implies a value of $313.86 (-1.9%), P/B (Peer) suggests $321.04 (+0.3%), EV/EBITDA (Peer) indicates $335.57 (+4.9%), and the Analyst Target stands at $311.83 (-2.6%). These methods collectively point to a valuation near the current trading level, reinforcing the 'Fairly Valued' consensus.
However, a notable divergence exists with two specific methods, leading to an exceptionally wide overall valuation range of $100.59 to $725.40. The P/S (Peer) method yields a significantly lower implied value of $100.59 (-68.6%), potentially reflecting the limited applicability of a pure revenue multiple for a high-margin, exchange-based business model. Conversely, the Discounted Cash Flow (DCF) analysis projects a substantially higher implied value of $725.40 (+126.7%), suggesting considerable upside if long-term free cash flow generation assumptions are realized. This wide spread in individual method outcomes highlights varying interpretations of CME's intrinsic value drivers and future growth potential.
Key Takeaways
- CME Group Inc. appears fairly valued based on the median of multiple valuation approaches, with most peer-based multiples and analyst targets closely aligning with the current share price.
- While most methods converge, the extreme divergence of the P/S and DCF methods creates a very wide valuation range, indicating significant uncertainty and differing views on CME's fundamental value drivers.
- The P/S method's low valuation may reflect its limited suitability for a high-margin, fee-based business, while the DCF's high valuation suggests strong long-term cash flow potential, contingent on robust growth assumptions.
Investment Implications
For investors, CME Group Inc.'s current valuation suggests it is trading at a reasonable level relative to its industry peers and prevailing market expectations. The consensus of 'Fairly Valued' implies that significant re-rating potential, based solely on current metrics, may be limited. However, the substantial upside indicated by the DCF model, which is typically sensitive to long-term growth and margin assumptions, suggests that investors with a more optimistic outlook on CME's future cash flow generation could see significant value. Conversely, the low valuation from the P/S multiple warrants caution, although its applicability to CME's specific business model should be carefully considered. Investors should conduct thorough due diligence into the underlying assumptions of the DCF model and evaluate the appropriateness of revenue multiples for CME. The wide valuation range underscores the importance of a clear investment thesis regarding CME's long-term growth trajectory and profitability to justify an investment decision.
Comprehensive Valuation Summary
Aggregated implied values from multiple valuation methods: P/E, P/B, EV/EBITDA, P/S (peer-based), DCF, and Analyst Targets
| Company | Current Price | Valuation Range | Median Value | Median Upside | Methods | Consensus |
|---|---|---|---|---|---|---|
| CME | $320.00 | $100.59 - $725.40 | $317.45 | -0.8% | 6 | Fairly Valued |
Valuation Details by Method
Implied values from each valuation methodology for individual companies
CME – CME Group Inc.
Current: $320.00
Fairly Valued
| Method | Implied Value | Upside/Downside | Basis |
|---|---|---|---|
| P/E (Peer) | $313.86 | -1.9% | Peer median P/E (24.8x) × Forward EPS ($12.64) |
| P/B (Peer) | $321.04 | +0.3% | Peer median P/B (3.43x) × Book Value per Share |
| EV/EBITDA (Peer) | $335.57 | +4.9% | Peer median EV/EBITDA (20.9x) × EBITDA - Net Debt |
| P/S (Peer) | $100.59 | -68.6% | Peer median P/S (4.73x) × Revenue per Share |
| DCF | $725.40 | +126.7% | Revenue × FCF Margin projection |
| Analyst Target | $311.83 | -2.6% | Consensus of 9 analysts |
| Median | $317.45 | -0.8% | Based on 6 methods |
Most Undervalued
- CME
Highest Analyst Upside
- CME